Format

Send to

Choose Destination
Eur J Cancer. 2016 Nov;68:134-147. doi: 10.1016/j.ejca.2016.09.010. Epub 2016 Oct 15.

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Author information

1
CHU Rennes, Service Hématologie Clinique, F-35033, Rennes, France.
2
Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces, Villejuif, F-94805, France; INSERM U1015, Villejuif, F-94805, France.
3
CHU Rennes, Service Hématologie Clinique, F-35033, Rennes, France; INSERM, U917, F-35043, Rennes, France. Electronic address: roch.houot@chu-rennes.fr.

Abstract

Downregulation/loss of the antigen presentation is a major immune escape mechanism in cancer. It allows tumour cells to become 'invisible' and avoid immune attack by antitumour T cells. In tumour harbouring properties of professional antigen presenting cells (i.e. tumour B cells in lymphoma), downregulation/loss of the antigen presentation may also prevent direct priming of naïve T cells by tumour cells. Here, we review treatments that may induce/restore antigen presentation by the tumour cells. These treatments may increase the generation of antitumour T cells and/or their capacity to recognise and eliminate tumour cells. By forcing tumour cells to present their antigens, these treatments may sensitise patients to T cell-based immunotherapies, including checkpoint inhibitors.

KEYWORDS:

Antigen presentation; Cancer; Checkpoint inhibitors; Immunotherapy

PMID:
27755997
DOI:
10.1016/j.ejca.2016.09.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center